Compounding Pharmacy Regulation and Office Use
Published Online: Thursday, November 14, 2013
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses his concern that in reaffirming section 503A of the Federal Food, Drug, and Cosmetic Act, H.R. 3204 (the Drug Quality and Security Act) would leave pharmacists who compound medications for office use by physicians and dentists in an ambiguous regulatory position. This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
Expanding upon efforts to implement the federal Drug Quality and Security Act enacted 1 year ago, the FDA today released 3 policy documents that assist companies that compound sterile drugs with registering as outsourcing facilities.
A New Jersey-based compounding pharmacy has voluntarily recalled 4 prescription preparations distributed in 4 states due to potential contamination.
New legislation comes 2 years after contaminated steroids from a Massachusetts compounding pharmacy cause meningitis outbreak.